Growth Hormone SecretagoguesWADA Prohibited
CJC-1295 No DAC
Synonyms: Modified GRF 1-29, Mod GRF 1-29, Sermorelin Analog
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Critical Safety & Regulatory Notice
CJC-1295 No DAC is classified as a regulated, unapproved, or research-only substance. Doping/Regulatory Status: Not FDA approved. Strictly prohibited by WADA under Section S2.. Clinical safety profiles for human use are deficient or not approved.
History & Discovery Timeline
CJC-1295 No DAC (Modified GRF 1-29) was developed by ConjuChem in the mid-2000s as a shorter-acting GHRH analog without the Drug Affinity Complex.
What it is: It is a synthetic tetrasubstituted 29-amino-acid peptide analog of Growth Hormone Releasing Hormone (GHRH). It falls under the Metabolic category.
Proposed Mechanisms & Research Findings: It stimulates the pituitary gland to release growth hormone by binding to GHRH receptors, prompting pulsatile growth hormone secretion.
Regulatory & Safety Status: It is not FDA approved. Online gray-market sourcing presents serious risks of hormone imbalances and unverified peptide purity.
Athletic & Anti-Doping Status: Strictly prohibited by WADA under Section S2. Use constitutes a major doping violation.
Understanding CJC-1295 No DAC Key Facts
Primary Target System:NEUROENDOCRINE
Residue Count / Length:31 Amino Acids
Primary Action & Category:GHRH Receptor Agonist (Growth Hormone Secretagogues)
Primary Receptors:GHRH Receptor (GHRHR)
Figure 1: Detailed molecular mechanism pathways of CJC-1295 No DAC (click to enlarge).